Fig. 4 | Scientific Reports

Fig. 4

From: The RASAL2 variant promotes aberrant RAS signaling and resistance to anti-EGFR therapy in colorectal cancer

Fig. 4

RASAL2 c.2423 A > G enhances the proliferation ability of CRC cells. The proliferation ability of CRC cells was assessed using the MTT assay in parental, vector-only, wild-type RASAL2 (c.2423 A > A), and mutant RASAL2 (c.2423 A > G) transfected HT29 (a) and LIM1215 cells (b). Cell viability was measured over 2 days, and results are presented as the percentage increase relative to day 0 for each cell line. Bar graphs (right) provide a visual representation of cell proliferation activity on day 2. Values are expressed as the mean ± SEM from three independent experiments. Statistical analysis was performed using Student’s t-test. ***p < 0.001.

Back to article page